XML 58 R39.htm IDEA: XBRL DOCUMENT v3.3.1.900
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Apr. 02, 2015
USD ($)
Oct. 18, 2013
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
item
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Summary Of Significant Accounting Policies            
Royalty and milestone payments received           $ 240,500
Number of product candidates under clinical development | item       1    
Advertising Costs            
Advertising expense       $ 2,300 $ 1,800 2,400
Cash discount (as a percent)       2.00%    
Discount reimbursement period after filling of prescription subject to discount       1 month    
Outstanding balance of the liability recognized in Non-cash royalty revenue         242,808 $ 18,104
Minimum            
Advertising Costs            
Discount taken off period after the quarter in which product shipped to the customer       1 month    
Period after the quarter in which prescription is filled for paying rebate       2 months    
Minimum | Managed Care Rebates            
Advertising Costs            
Period after the quarter in which prescription is filled for rebate       1 month    
Minimum | Medicare Part D Coverage Gap Rebates            
Advertising Costs            
Period after the quarter in which prescription is filled for rebate       2 months    
Maximum            
Advertising Costs            
Product return period prior to expiration       6 months    
Period after expiration for accepting unsalable product       12 months    
Discount taken off period after the quarter in which product shipped to the customer       2 months    
Period after the quarter in which prescription is filled for paying rebate       3 months    
Maximum | Managed Care Rebates            
Advertising Costs            
Period after the quarter in which prescription is filled for rebate       3 months    
Maximum | Medicare Part D Coverage Gap Rebates            
Advertising Costs            
Period after the quarter in which prescription is filled for rebate       3 months    
NUCYNTA | Minimum            
Advertising Costs            
Product shelf-life       24 months    
NUCYNTA | Maximum            
Advertising Costs            
Product shelf-life       36 months    
Gralise | Minimum            
Advertising Costs            
Product shelf-life       24 months    
Gralise | Maximum            
Advertising Costs            
Product shelf-life       36 months    
Zipsor            
Advertising Costs            
Product shelf-life       36 months    
500mg Glumetza            
Advertising Costs            
Product shelf-life       48 months    
1000mg Glumetza | Minimum            
Advertising Costs            
Product shelf-life       24 months    
1000mg Glumetza | Maximum            
Advertising Costs            
Product shelf-life       36 months    
CAMBIA | Minimum            
Advertising Costs            
Product shelf-life       24 months    
CAMBIA | Maximum            
Advertising Costs            
Product shelf-life       48 months    
Lazanda | Minimum            
Advertising Costs            
Product shelf-life       24 months    
Lazanda | Maximum            
Advertising Costs            
Product shelf-life       36 months    
Furniture and office equipment | Minimum            
Property and Equipment            
Estimated useful lives       3 years    
Furniture and office equipment | Maximum            
Property and Equipment            
Estimated useful lives       5 years    
Machinery and Equipment | Minimum            
Property and Equipment            
Estimated useful lives       5 years    
Machinery and Equipment | Maximum            
Property and Equipment            
Estimated useful lives       7 years    
Laboratory equipment | Minimum            
Property and Equipment            
Estimated useful lives       3 years    
Laboratory equipment | Maximum            
Property and Equipment            
Estimated useful lives       5 years    
Senior Notes            
Summary Of Significant Accounting Policies            
Aggregate principal amount of notes issued $ 575,000          
Proceeds from the issuance of debt $ 562,000          
Liability related to sale of future royalties            
Advertising Costs            
Outstanding balance of the liability recognized in Non-cash royalty revenue     $ 147,000   $ 242,800  
Liability related to sale of future royalties | PDL BioPharma            
Summary Of Significant Accounting Policies            
Royalty and milestone payments received   $ 240,500